ArticleFrontiers in cellular and infection microbiology2026
Exhaled breath condensate metabolomics reveals inflammation-associated metabolic alterations and metabolites with possible relevance to virulence-related processes in pulmonary cryptococcosis.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To analyze metabolic alterations associated with pulmonary cryptococcosis (PC) using metabolomic profiling of exhaled breath condensate (EBC) and investigate metabolic differences between fungal infections through comparison with patients with pulmonary aspergillosis (PA). Methods: We enrolled 32 patients with PC, 16 patients with PA, and 14 healthy controls (NC) between September 2022 and September 2025. EBC samples were analyzed using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Differential metabolites were identified using t-test, fold-change and PLS-DA. Discriminatory ability was evaluated using receiver operating characteristic (ROC) curves, and potential biological significance was explored through correlation analysis and KEGG pathway. Results: Forty-five differential metabolites were putatively annotated in the PC versus NC comparison, with 24 remaining significant after FDR correction (q < 0.05). Pathway analysis nominally implicated glycerophospholipid and amino acid metabolism pathways, suggesting that dysregulated lipid metabolism may contribute to the pathogenesis and progression of PC. ROC analysis in this single-center discovery cohort, without independent validation, revealed that alpha-ionone (AUC = 0.8482) and N,N-dimethylsphingosine (AUC = 0.8348) exhibited favorable preliminary discriminatory potential, reflecting distinct metabolic alterations associated with PC. Phenethylamine and phytosphingosine showed moderate preliminary discriminatory potential (AUC = 0.7679 and 0.7567, respectively), and their altered levels raise the possibility of an association with Cryptococcus virulence-related processes. Phytosphingosine was positively correlated with interleukin-6 (IL-6) (r = 0.73, raw P = 0.040), although not after FDR correction (q = 0.423). PC versus PA comparison putatively annotated eight differential metabolites (raw P < 0.05), none remaining significant after FDR correction (q = 0.535); these metabolites were nominally implicated in glycerophospholipid metabolism and polyunsaturated fatty acid-related pathways. Beta-ionone, butaxamine, and cimiracemoside D exhibited gradient trends across the three groups, while cimiracemoside D was positively correlated with erythrocyte sedimentation rate (ESR) (ρ = 0.48, raw P = 0.022), although not after FDR correction (q = 0.423), suggesting metabolic differences between fungal infections may reflect differences in inflammatory responses. Discussion: EBC metabolomic analysis revealed significant inflammation-related and lipid metabolism-related alterations in patients with PC versus healthy controls, while comparisons with PA suggested that these metabolic changes mainly reflected shared host responses rather than pathogen-specific features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.